Aura Biosciences (AURA) Competitors $6.04 -0.14 (-2.27%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. CDTX, PAHC, ARDX, TWST, VERA, AVDL, COGT, SNDX, JANX, and SDGRShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Ardelyx (ARDX), Twist Bioscience (TWST), Vera Therapeutics (VERA), Avadel Pharmaceuticals (AVDL), Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX), Janux Therapeutics (JANX), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors Cidara Therapeutics Phibro Animal Health Ardelyx Twist Bioscience Vera Therapeutics Avadel Pharmaceuticals Cogent Biosciences Syndax Pharmaceuticals Janux Therapeutics Schrodinger Cidara Therapeutics (NASDAQ:CDTX) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Do insiders and institutionals believe in CDTX or AURA? 35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 7.6% of Cidara Therapeutics shares are held by insiders. Comparatively, 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, CDTX or AURA? Cidara Therapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Which has stronger earnings & valuation, CDTX or AURA? Aura Biosciences has lower revenue, but higher earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.27M1,308.04-$169.83M-$11.13-5.89Aura BiosciencesN/AN/A-$86.92M-$1.96-3.08 Does the media favor CDTX or AURA? In the previous week, Cidara Therapeutics and Cidara Therapeutics both had 3 articles in the media. Cidara Therapeutics' average media sentiment score of 1.65 beat Aura Biosciences' score of 1.55 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aura Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is CDTX or AURA more profitable? Cidara Therapeutics' return on equity of -50.81% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -50.81% -42.46% Aura Biosciences N/A -64.44%-54.24% Do analysts prefer CDTX or AURA? Cidara Therapeutics currently has a consensus target price of $64.14, suggesting a potential downside of 2.08%. Aura Biosciences has a consensus target price of $22.00, suggesting a potential upside of 264.24%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Aura Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11 SummaryCidara Therapeutics beats Aura Biosciences on 7 of the 13 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$375.21M$3.11B$5.75B$10.26BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-3.0821.3775.2626.44Price / SalesN/A240.13456.1288.47Price / CashN/A44.4425.8129.91Price / Book1.999.6413.256.27Net Income-$86.92M-$53.20M$3.29B$270.47M7 Day Performance-6.65%0.17%0.68%2.74%1 Month Performance-10.12%3.98%4.54%5.95%1 Year Performance-40.02%9.16%73.36%25.97% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences2.2403 of 5 stars$6.04-2.3%$22.00+264.2%-38.6%$375.21MN/A-3.0850Positive NewsCDTXCidara Therapeutics3.1685 of 5 stars$62.15-1.6%$64.14+3.2%+449.6%$1.60B$1.27M-5.5890Positive NewsPAHCPhibro Animal Health4.4517 of 5 stars$39.43-0.1%$28.40-28.0%+80.2%$1.60B$1.30B33.422,475Analyst RevisionARDXArdelyx4.6217 of 5 stars$6.59+1.1%$11.70+77.5%+4.8%$1.57B$333.61M-28.6590Positive NewsTWSTTwist Bioscience3.9681 of 5 stars$26.25+1.9%$49.40+88.2%-46.1%$1.55B$312.97M-18.10990VERAVera Therapeutics2.745 of 5 stars$24.75+2.3%$63.00+154.5%-36.6%$1.54BN/A-6.9140Positive NewsAVDLAvadel Pharmaceuticals3.0866 of 5 stars$15.38-2.4%$20.86+35.6%+12.4%$1.53B$221.08M-512.6770Positive NewsCOGTCogent Biosciences3.0485 of 5 stars$12.68-2.8%$20.00+57.7%+19.1%$1.49BN/A-7.1280Positive NewsSNDXSyndax Pharmaceuticals3.9171 of 5 stars$16.33-4.2%$38.89+138.1%-18.7%$1.47B$23.68M-4.20110JANXJanux Therapeutics3.1036 of 5 stars$24.81+3.5%$85.55+244.8%-51.9%$1.44B$10.59M-13.7830SDGRSchrodinger3.4053 of 5 stars$19.44+1.6%$27.83+43.2%-10.4%$1.41B$207.54M-7.84790Positive News Related Companies and Tools Related Companies Cidara Therapeutics Competitors Phibro Animal Health Competitors Ardelyx Competitors Twist Bioscience Competitors Vera Therapeutics Competitors Avadel Pharmaceuticals Competitors Cogent Biosciences Competitors Syndax Pharmaceuticals Competitors Janux Therapeutics Competitors Schrodinger Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AURA Stock Alerts